METTL3 and hepatocellular carcinoma: Apart from the HCC-promoting effect, METTL3 has been reported to be closely associated with sorafenib resistance in chemotherapy of advanced HCC patients, described as a reduced expression of METTL3 in sorafenib-resistance HCC.